CN1742912A - Medicine for treating and preventing chronic obstractive pneumonia - Google Patents
Medicine for treating and preventing chronic obstractive pneumonia Download PDFInfo
- Publication number
- CN1742912A CN1742912A CNA2005100032234A CN200510003223A CN1742912A CN 1742912 A CN1742912 A CN 1742912A CN A2005100032234 A CNA2005100032234 A CN A2005100032234A CN 200510003223 A CN200510003223 A CN 200510003223A CN 1742912 A CN1742912 A CN 1742912A
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- lung
- chronic obstructive
- obstructive pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine for effectively curing and preventing chronic obstructive disease of lung with obvious therapeutic effect. It is made up by using (by weight portion) 1-30 portions of astragalus root, 1-20 portions of pilose asiabell root, 1-15 portions of bile-processed arisaema root and 1-15 portions of silkworm through a certain preparation process.
Description
Technical field:
The present invention relates to a kind of medicine with treatment and prevention chronic obstructive pulmonary disease.
Background technology:
Chronic obstructive pulmonary disease (Chronic Obstractive Polmonary Disease, COPD) be meant chronic bronchitis with airflow obstruction feature and (or) disease such as emphysema, this disease has become the chronic respiratory failure chief reason in recent years.Because disease is and slowly carries out sexual development, has a strong impact on patient's work capacity and quality of life.Attention helps delaying advancing of disease to the treatment of COPD stable phase.Though it is more to treat at present the medicine of this disease, ubiquity the less-than-ideal problem of curative effect, and existing medicine great majority be Western medicine, though these Western medicine have certain curative effect, it exists the phenomenon of toxic and side effects also to compare seriously.Therefore at present it is undesirable and have a shortcoming of certain toxic and side effects that treatment and prevention chronic obstructive pulmonary disease thing exist result of use.
Summary of the invention:
Content of the present invention is: provide a kind of therapeutic effect better, the treatment that has no side effect and the Chinese medicine of prevention chronic obstructive pulmonary disease, to overcome the deficiencies in the prior art.
The present invention is achieved in that this medicine makes medicament by the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, Bombyx Batryticatus four flavor Chinese medicines, and each Chinese medicine proportioning by weight of distinguishing the flavor of is: 1～30 part of the Radix Astragali, 1～20 part of Radix Codonopsis, 1～15 part of Arisaema Cum Bile, 1～15 part of Bombyx Batryticatus.
Each Chinese medicine best proportioning by weight of distinguishing the flavor of is: respectively 10 parts of the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, Bombyx Batryticatus.
Said medicament is a said dosage form on any pharmaceutics.
Said medicament is: tablet, oral liquid formulations, concentrated granular electuary or capsule preparations.
In technique scheme, the Chinese medicine of respectively distinguishing the flavor of in the compositing formula has following effect:
Prescription of the present invention forms 1: the Radix Astragali.Sweet, the tepor of the Radix Astragali is gone into spleen channel, energy tonifying Qi and lifting yang, strengthening superficial resistance to stop perspiration, expelling pus and toxin by strengthening QI, inducing diuresis to remove edema.With using powerful QI invigorating effect is arranged with Radix Codonopsis.Because of the yang invigorating effect is arranged, can be used for the disease of sinking of QI of middle-JIAO, also be used for the disease of the spontaneous perspiration of weak failure of superficial QI to protect the body against disease.Because of the energy QI invigorating and body resistance strengthening, can be used for the positive QI-insufficiency of carbuncle and ulcer, not diabrosis for a long time or of a specified duration bursting are not held back the person.Because of QI invigorating transporting sun with diuretic, so can control the deficiency syndrome edema caused by wind-dampness.Modern study proves that the Radix Astragali contains saccharide, lymphatic temperament, choline, several aminoacid, and its pharmacology is: the Radix Astragali has the effect of strengthen shrinking to heart, and to because of poisoning or tiredly sinking into depleted heart, its cardiotonic is more remarkable.The precious medicine finished product of the ginseng stilbene lung that adopts the present invention to make shows external that through clinical experiment dysentery bacterium, anthrax bacillus, first, group B streptococcus, diphtheria corynebacterium, bacillus pseudodiphthericus, Staphylococcus citreus, bacillus subtilis etc. are all had inhibitory action.
Prescription of the present invention forms 2: Radix Codonopsis.Radix Codonopsis is sweet flat, goes into spleen, lung meridian, invigorating the spleen and replenishing QI.Modern study proves: Radix Codonopsis contains Saponin, alkaloid, protein, vitamin B1, B2, inulin etc.Its pharmacology is: Radix Codonopsis has excitation to nervous system, can increase Abwehrkraft des Koepers, and tame rabbit erythrocyte and hemoglobin are increased, and makes peripheral vasodilation and blood pressure lowering, and can suppress adrenergic boosting.Radix Codonopsis descends for the leukocyte that chemotherapy and radiotherapy cause, the effect that makes its rising is arranged.
Prescription of the present invention forms 3: Arisaema Cum Bile.Arisaema Cum Bile is that Rhizoma Arisaematis is concocted and got through Fel Bovis seu Bubali, goes its dry property.Compendium of Material Medica cloud: " it is then not dry to get Fel Bovis seu Bubali ".The Arisaema Cum Bile nature and flavor are bitter cool, and the dispelling wind and relieving convulsion that can reduce phlegm can be controlled the meridians wind-phlegm.
Prescription of the present invention forms 4: Bombyx Batryticatus.The salty suffering of Bombyx Batryticatus nature and flavor is flat, goes into the liver lung meridian.Dispel the wind, spasmolytic, reduce phlegm, eliminating stagnation.The Compendium of Material Medica cloud: " the wind-phlegm tuberculosis of loosing, scrofula, wind syndrome of head, wind worm toothache, skin wind skin ulcer, erysipelas is had an itch, intermittent fever due to phlegm crux, married woman's galactostasis ".Cloud again: " Bombyx Batryticatus, the sick wind person of silkworm also.Expelling wind and eliminating phlegm, the joint property of loosing warp, so-called because of its gas phase sense with the meaning person of making it also ".Show through modern study: Bombyx Batryticatus contains fat and protein, and its protein has the adrenocortical effect of stimulation.
Owing to adopted technique scheme, the present invention has relieving cough and resolving phlegm, clear respectful lung machine, unobstructed blood vessels, replenishing QI to invigorate the spleen, the effect of the solid gold of tonifying the lung.The present invention to help lung, makes lung can reach main gas with invigorating the spleen and replenishing QI, and therefore the respectful purpose of breathing with department of falling has the effect of safeguarding and consolidating lung, spleen.
The present invention proves through experimentation, the rat of chronic obstructive disease of lung is had good treatment and preventive effect, and preventive effect obviously is better than therapeutical effect.Clinical practice is to chronic bronchitis, asthma, emphysema, patients' such as pulmonary heart disease cough, cough up phlegm, improvement that tachypnea gas is tired and keep respiratory tract unobstructed curative effect preferably arranged.Patients with chronic obstructive pulmonary diseases there is good help.
Therefore the present invention compares with the various kinds of drug of prevention chronic obstructive pulmonary disease with existing treatment, and the present invention has the advantage that therapeutic effect is good, have no side effect.
The specific embodiment:
Embodiments of the invention 1: get the Radix Astragali 30 grams, Radix Codonopsis 20 grams, Arisaema Cum Bile 10 grams, Bombyx Batryticatus 10 grams, and add after 500 ml waters fully are mixed into medicinal liquid, the processing technology of oral liquid is endured medicinal liquid and is concentrated into 100 milliliters routinely again, can make oral liquid formulations of the present invention.The instructions about how to take medicine of oral liquid formulations are: every day 2-3 time, each 10-20 milliliter is used warm water delivery service.
Embodiments of the invention 2: get the Radix Astragali 20 grams, Radix Codonopsis 10 grams, Arisaema Cum Bile 15 grams, Bombyx Batryticatus 15 grams, and add after 500 ml waters fully are mixed into medicinal liquid, the processing technology of oral liquid is endured medicinal liquid and is concentrated into 100 milliliters routinely again, can make oral liquid formulations of the present invention.The instructions about how to take medicine of oral liquid formulations are: every day 2-3 time, each 10-20 milliliter is used warm water delivery service.
Embodiments of the invention 3: get the Radix Astragali 10 grams, Radix Codonopsis 10 grams, Arisaema Cum Bile 5 grams, Bombyx Batryticatus 10 grams, and add after 500 ml waters fully are mixed into medicinal liquid, the processing technology of oral liquid is endured medicinal liquid and is concentrated into 100 milliliters routinely again, can make oral liquid formulations of the present invention.The instructions about how to take medicine of oral liquid formulations are: every day 2-3 time, each 10-20 milliliter is used warm water delivery service.
Embodiments of the invention 4: get each 10 gram of the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, Bombyx Batryticatus, and add after 500 ml waters fully are mixed into medicinal liquid, the processing technology of oral liquid is endured medicinal liquid and is concentrated into 100 milliliters routinely again, can make oral liquid formulations of the present invention.The instructions about how to take medicine of oral liquid formulations are: every day 2-3 time, each 30-50 milliliter is used warm water delivery service.
Embodiments of the invention 5: get the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, each 10 gram of Bombyx Batryticatus, fully mix the back and break into thin medicated powder, the processing technology of pharmaceutical capsules preparation incapsulates medicated powder by every 0.3 gram routinely, can make capsule preparations of the present invention.The instructions about how to take medicine of capsule preparations are: every day 2-3 time, each 3, use warm water delivery service.
Embodiments of the invention 6: get the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, each 10 gram of Bombyx Batryticatus, fully mix the back and break into thin medicated powder, the processing technology of tablet medicine is pressed into tablet with medicated powder by every 0.3 gram routinely, can make tablet of the present invention.The instructions about how to take medicine of tablet are: every day 2-3 time, each 3, use warm water delivery service.
Embodiments of the invention 7: get the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, each 10 gram of Bombyx Batryticatus, break into thin medicated powder after fully mixing, and add after 500 ml waters fully are mixed into medicinal liquid, medicinal liquid is brewed into paste, and be condensed into granule, the processing technology of pharmaceutical capsules preparation incapsulates granule by every 0.3 gram routinely again, can make another kind of capsule preparations of the present invention.The instructions about how to take medicine of this capsule preparations are: every day 2-3 time, each 1, use warm water delivery service.
Embodiments of the invention 8: get the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, each 1O gram of Bombyx Batryticatus, break into thin medicated powder after fully mixing, and add after 500 ml waters fully are mixed into medicinal liquid, medicinal liquid is brewed into paste, and be condensed into granule, then granule is packed by every bag 0.5 gram with non-toxic plastic bag, can be made concentrated granular electuary preparation of the present invention.The instructions about how to take medicine of concentrated granular electuary preparation are: every day 2-3 time, each 1 bag, take after mixing it with hot water.
The finished medicines name that adopts the present invention to make is called: " ginseng stilbene lung treasured ", be divided into 4 kinds of dosage forms and this medicine and carried out clinical experiment, be to adopt finished medicines of the present invention " ginseng stilbene lung treasured " treatment chronic obstructive pulmonary disease stable phase 30 routine clinical observations below, so that curative effect of the present invention is further described:
The 30 routine clinical observations of the precious treatment of ginseng stilbene lung chronic obstructive pulmonary disease stable phase
[summary] purpose is observed the curative effect of ginseng stilbene lung treasured to chronic obstructive pulmonary disease (COPD) stable phase.Method is divided into 2 groups at random with 60 routine COPD stable phase patients, and treatment is organized 30 examples and taken ginseng stilbene lung treasured, and matched group 30 examples adopt conventional cough-relieving, symptomatic treatment reduces phlegm, relievings asthma.Observe 2 groups of treatment front and back clinical symptoms and relapse rate.The result: treatment is organized clinical cardinal symptom sign integration and relapse rate than matched group all have clear improvement (P＜0.05).The precious treatment of conclusion ginseng stilbene lung COPD stable phase has the good preventing therapeutic effect.
[key word] chronic obstructive pulmonary disease stable phase; Ginseng stilbene lung treasured; Clinical efficacy
Chronic obstructive pulmonary disease (Chronic Obstractive PolmonaryDisease, COPD) be meant chronic bronchitis with airflow obstruction feature and (or) emphysema, become the chronic respiratory failure chief reason in recent years.Because disease is and slowly carries out sexual development, has a strong impact on patient's work capacity and quality of life.Attention helps delaying advancing of disease to the treatment of COPD stable phase.The author adopts the precious treatment of ginseng stilbene lung COPD (catabasis) 30 examples, and contrasts with western medicine 30 examples, and obtaining effect is excellent than the latter, now is reported as follows.
1, data and method
1.1 this group of physical data case is COPD patient due to chronic bronchitis and the obstructive emphysema, 30 examples are organized in treatment, male 25 examples, women 5 examples, 52～74 years old age, average (64.5 ± 7.0) year; The course of disease 8.74 ± 2.35 years.Matched group 30 examples, male 26 examples, women 4 examples; 48～70 years old age, average (65.8 ± 6.80 years old); The course of disease 9.01 ± 3.21 years.All case all meets " chronic obstructive pulmonary disease (COPD) diagnosis and treatment guide " (Chinese tuberculosis and breathing magazine .2002 that Chinese Medical Association's respiratory disease credit meeting in 2002 is formulated, 25 (8): 453 ∽ 460) diagnostic criteria, two groups of patient ages, sex, course of disease there was no significant difference (P＞0.05) have comparability.
1.2 Therapeutic Method treatment group patient joins the precious treatment of stilbene lung at stable phase, be 1 course of treatment January.The Chinese patent medicine that the matched group patient only obeys conventional cough-relieving, reduces phlegm, relievings asthma.If acute attack in therapeutic process, occurs, all suit the medicine to the illness or anti-infective therapy for 2 groups.
1.3 2 groups of observation periods of observational technique are 1 year.Treat 2 courses of treatment before 2 groups of autumns, winters change, and carry out itemized record.Main observed content: cough, cough up phlegm and pant in (1) treatment front and back, the variation of moist rale.(2) acute attack number of times.
1.4 the weight of criterion of therapeutical effect clinical symptoms and sign carries out with reference to " the chronic bronchitis clinical diagnosis and the curative effect judging standard " of revision in 1979.(1) cough: 0 minute, do not have cough; 1 minute (slightly), be interrupted cough daytime, do not influence orthobiosis and work; 2 minutes (moderate), symptom is between slight and severe; 3 minutes (severe), the frequent or apasm of coughing of cough round the clock influences work and sleep.(2) cough up phlegm: 0 minute, nothing was coughed up phlegm; 1 minute (lacking), be interrupted cough up phlegm 10～50ml or night and the early morning 5～25ml that coughs up phlegm daytime; 2 minutes (in), the 51～100ml that coughs up phlegm round the clock, or the 25～50ml that coughs up phlegm in night and early morning; 3 minutes (many) cough up phlegm more than the 100ml round the clock, or night and early morning cough up phlegm more than the 50ml.(3) pant: 0 minute, nothing was panted; There was outbreak 1 minute (slightly), and degree is light, do not influence sleep and movable; 2 minutes (moderate), the state of an illness is between slight and severe; 3 minutes (severe) pants obviously, can not put down for sleeping in, influence sleep and movable.(4) wheezing sound, moist rale: 0 minute, no rale; 1 minute (lacking), hear, or occur in cough, the dark fast back of breathing; 2 minutes (in), scatter; 3 minutes (weight) is abound with.
2, result
2.12 the situation of change of clinical cardinal symptom and sign integration before and after the group treatment
Integration changes relatively branch, x ± s before 2 groups of clinical cardinal symptoms of table 1 and the sign treatment
| Group | n | Cough | Cough up phlegm | Pant | Wheezing sound, rale | |
| Treatment group matched group | 30 30 | After controlling before controlling after controlling before controlling | 1.79±0.53 0.84±0.55 1.82±0.46 1.03±0.57 | 1.65±0.48 0.68±0.49 1.68±0.51 0.99±0.75 | 1.42±0.78 0.94±0.53 1.46±0.68 1.11±0.41 | 0.88±0.65 0.65±0.48 0.97±0.62 0.75±0.54 |
Relatively preceding with the treatment of this group, P＜0.05; With after the treatment of control group relatively, Δ P＜0.05 treatment group cough after treatment, cough up phlegm, pant symptom and wheezing sound, rale all is significantly improved; Relatively the clinical symptoms improvement is also obvious with matched group.
2.2 30 examples are organized in the treatment of acute attack frequency, no acute attack person's 7 examples in 1 year, person's 12 examples of showing effect 1 time, 2～4 person's 11 examples; Matched group 30 examples, no acute attack person's 2 examples in 1 year, person's 7 examples of showing effect 1 time, 2～4 person's 21 examples.2 groups of relatively treatment groups obviously are better than matched group (P＜0.05).
3, discuss
COPD belongs to traditional Chinese medical science pulmonary distension category, thinks that it is to cause impairment of dispersing and descending function of the lung by Different types of etiopathogenises, coughs, expectorant, breathes heavily all diseases and occur in succession, with the passing of time consumes impairing the lung gas, undermines the spleen kidney, accumulates in expectorant is turbid, becomes to give birth to the stasis of blood and stagnate, and forms the card of the qi-asthenia phlegm stasis of blood, and it is marked on lung, and it is at the spleen kidney.But study carefully its essence, the closest with the lung relation.Blood stasis due to qi deficiency is double, and to press from both sides expectorant turbid be the primary disease main pathological basis, and blood stasis due to qi deficiency runs through whole pathological process.It is dirty that pathological changes relates generally to lung spleen kidney three, and it is the important step that the touching difficulty of primary disease heals that the empty stasis of blood is harmonious.The traditional Chinese medical science is seted forth one's views with deficiency in origin and excess in superficiality, sets upright and gets rid of evils and take into account, and the typing opinion is controlled by stages, and acute stage is controlled when eliminating evil based on the domination of pathogen, and the catabasis is controlled with tonify deficiency based on deficiency in origin.Ginseng stilbene lung treasured is the clinical experience side that the author treats COPD lung spleen nephrasthenia syndrome.This side be on the basis of BUFEI TANG at the pathogenesis of COPD lung spleen nephrasthenia syndrome, deduct sour sweet taste greasy Fructus Schisandrae Chinensis, Radix Rehmanniae Preparata, with the Radix Ginseng of the easy warm-dryness syndrome of Radix Codonopsis, add the Fructus Psoraleae of reinforcing the kidney and supporting YANG, the Radix Salviae Miltiorrhizae of blood circulation promoting and blood stasis dispelling forms with the easy Radix Asteris of the Radix Stemonae of expelling phlegm for arresting cough.The Radix Astragali, Radix Codonopsis invigorating the spleen to benefit the lung in the side, strengthening the body resistance, energy human body immunity improving power strengthens resistance against diseases, Fructus Psoraleae the kidney warming sun, excessive fire benefit soil, the energy coronary artery dilating strengthens myocardial contraction, and antibacterial action is arranged, the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, the expansion pulmonary artery alleviates pulmonary hypertension, microcirculation improvement.Radix Stemonae nourishing the lung to arrest cough has the central antitussive effect, lax bronchial smooth muscle.The Cortex Mori eliminating pathogen from the lung for relieving asthma, inducing diuresis to remove edema.The same usefulness of all medicines can the QI invigorating tonify deficiency, and eliminate stagnation and dissolve phlegm alleviates clinical symptoms, delays the formation of pulmonary hypertension, thereby stops further developing of disease.
Claims (4)
1, the medicine of a kind of treatment and prevention chronic obstructive pulmonary disease, it is characterized in that: this medicine is made medicament by the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, Bombyx Batryticatus four flavor Chinese medicines, and each Chinese medicine proportioning by weight of distinguishing the flavor of is: 1～30 part of the Radix Astragali, 1～20 part of Radix Codonopsis, 1～15 part of Arisaema Cum Bile, 1～15 part of Bombyx Batryticatus.
2, the medicine of treatment according to claim 1 and prevention chronic obstructive pulmonary disease, it is characterized in that: each Chinese medicine best proportioning by weight of distinguishing the flavor of is: respectively 10 parts of the Radix Astragali, Radix Codonopsis, Arisaema Cum Bile, Bombyx Batryticatus.
3, the medicine of treatment according to claim 1 and prevention chronic obstructive pulmonary disease, it is characterized in that: said medicament is a said dosage form on any pharmaceutics.
4, according to the medicine of claim 1 or 3 described treatments and prevention chronic obstructive pulmonary disease, it is characterized in that: said medicament is: tablet, oral liquid formulations, concentrated granular electuary or capsule preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100032234A CN100389802C (en) | 2005-09-27 | 2005-09-27 | Medicine for treating and preventing chronic obstractive pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100032234A CN100389802C (en) | 2005-09-27 | 2005-09-27 | Medicine for treating and preventing chronic obstractive pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1742912A true CN1742912A (en) | 2006-03-08 |
| CN100389802C CN100389802C (en) | 2008-05-28 |
Family
ID=36138537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100032234A Expired - Fee Related CN100389802C (en) | 2005-09-27 | 2005-09-27 | Medicine for treating and preventing chronic obstractive pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389802C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028331B (en) * | 2007-04-10 | 2010-09-08 | 丽珠集团利民制药厂 | Pharmaceutical use of Radix codonopsis and Radix Astragali composition |
| CN102258688A (en) * | 2011-07-21 | 2011-11-30 | 河南中医学院 | Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD) |
| CN102614485A (en) * | 2012-04-09 | 2012-08-01 | 邹德奇 | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease with syndrome of insufficiency of lung, spleen and kidney on stationary phase |
| CN104840745A (en) * | 2015-05-04 | 2015-08-19 | 崔红萍 | Chinese medicine patch for curing chronic obstructive pulmonary disease |
| CN105727031A (en) * | 2016-03-30 | 2016-07-06 | 赵瑜飞 | Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease |
| CN106177052A (en) * | 2016-07-26 | 2016-12-07 | 李洪磊 | A kind of Chinese medicine preparation treating deficiency type of QI of the lung and kidney chronic obstructive emphysema |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1136885C (en) * | 2001-02-23 | 2004-02-04 | 邓万发 | Chinese medicine for treating dyspneic cough effectively |
-
2005
- 2005-09-27 CN CNB2005100032234A patent/CN100389802C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028331B (en) * | 2007-04-10 | 2010-09-08 | 丽珠集团利民制药厂 | Pharmaceutical use of Radix codonopsis and Radix Astragali composition |
| CN102258688A (en) * | 2011-07-21 | 2011-11-30 | 河南中医学院 | Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD) |
| CN102258688B (en) * | 2011-07-21 | 2012-07-25 | 河南中医学院 | Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD) |
| CN102614485A (en) * | 2012-04-09 | 2012-08-01 | 邹德奇 | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease with syndrome of insufficiency of lung, spleen and kidney on stationary phase |
| CN104840745A (en) * | 2015-05-04 | 2015-08-19 | 崔红萍 | Chinese medicine patch for curing chronic obstructive pulmonary disease |
| CN105727031A (en) * | 2016-03-30 | 2016-07-06 | 赵瑜飞 | Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease |
| CN106177052A (en) * | 2016-07-26 | 2016-12-07 | 李洪磊 | A kind of Chinese medicine preparation treating deficiency type of QI of the lung and kidney chronic obstructive emphysema |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100389802C (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1270043A (en) | Medicine for treating hemicrania | |
| CN101549101B (en) | Traditional Chinese medicine for treating pneumoconiosis and drug-tolerant pulmonary tuberculosis and preparation method thereof | |
| CN100389802C (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN1943754A (en) | A Medicine for treatment of gastrointestinal diseases | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN104623148A (en) | Medicament for treating cough and asthma and preparation method of oral liquid thereof | |
| CN108066706B (en) | Traditional Chinese medicine jaundice-removing plaster for treating icteric hepatitis | |
| CN1259964C (en) | Medicine for treating and preventing chronic obstructive pulmonary disease | |
| CN104940419A (en) | Traditional Chinese medicine capable of preventing colds and allergies and enhancing immunity | |
| CN103251813A (en) | Medicine for treating chronic bronchitis type tussive and preparation method thereof | |
| CN102614322A (en) | Medicinal composition for treating child asthmatic suffocating pneumonia | |
| CN102783645B (en) | Health care product for enhancing immunity | |
| CN106110244A (en) | Powder for relieving cough and asthma | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method | |
| CN101972394B (en) | Traditional Chinese medical external-use powder for treating children pulmonitis and preparation method thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN1112204C (en) | Traditional Chinese powder medicine for treating cough and preparation process thereof | |
| CN105853749A (en) | Pharmaceutical preparation for treating chronic pneumonia and preparing method | |
| CN104906495A (en) | Hypertension symptom improvement medicine mainly using rhodiola rosea | |
| CN102380035B (en) | Common coltsfoot flower, dwarf lilyturf tuber, white mulberry root-bark, ginkgo seed, whiteflower hogfennel root, elaeagnus pungens and Chinese wolfberry root-bark decoction for treating bronchial asthma | |
| CN105250645A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN100394937C (en) | Medicine for preventing and treating cardiac and cerebral vascular diseases | |
| CN104587297A (en) | Traditional Chinese medicine capsule for treating scleroderma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 Termination date: 20100927 |